InVivoMab anti-mouse 4-1BBL (CD137L) BE0110-R005mg from Bio X Cell | Biocompare.com

Supplier Images

InVivoMab anti-mouse 4-1BBL (CD137L)

Be the first to write a review!

Citations:

Supplier Page from
Bio X Cell for
InVivoMab anti-mouse 4-1BBL (CD137L)

The InVivoMab anti-mouse 4-1BBL (CD137L) Antibody from Bio X Cell is a Rat Monoclonal antibody to TNFSF4. This antibody recognizes Mouse antigen. The InVivoMab anti-mouse 4-1BBL (CD137L) Antibody has been validated for the following applications: EIA, Immunoassay, In Vivo, Block/Neutralize/Inhibit, and ELISA.

Description

Bio X Cell InVivoMAb anti-mouse 4-1BBL (CD137L) Monoclonal Antibody has the following reported applications: in vivo 4-1BBL blockade, ELISA. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMab anti-mouse 4-1BBL (CD137L)
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0110-R005mg
Quantity5 mg
Applicationsin vivo 4-1BBL blockade, ELISA
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
ReactivityMouse
Target4-1BBL
IsotypeIgG2a, κ
CloneTKS-1
Hostrat
NCBI Full Gene Nametumor necrosis factor (ligand) superfamily, member 4
NCBI Gene AliasesAth-1, Ath1, CD134L, OX-40L, Ox40l, TXGP1, Tnlg2b, Txgp1l, gp34
ClonalityMonoclonal
ImmunogenMouse 4-1BBL transfected NRK cells
Antibody TypePrimary Antibody
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 7.0, Contains no stabilizers or preservatives
Research AreaCancer Biology, Immune Checkpoint Protein, Immunology

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1Journal for immunotherapy of cancerAugust 10, 2019Thomas S, Kuncheria L, Roulstone V, Kyula JN, Mansfield D, Bommareddy PK, Smith H, Kaufman HL, Harrington KJ, Coffin RS.

(2) The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansioneLifeAugust 11, 2015Welten SP, Redeker A, Franken KL, Oduro JD, Ossendorp F, Čičin-Šain L, Melief CJ, Aichele P, Arens R.

(3) Comparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responsesJournal of immunology (Baltimore, Md. : 1950)August 15, 2010Kurche JS, Burchill MA, Sanchez PJ, Haluszczak C, Kedl RM.

Be the First to Write a Review!